SAM
KALV

Smartleaf Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Smartleaf Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6K Hold
575
– – ﹤0.01% 2300
2025
Q4 		$9.02K Buy
575
+322
+127% +$4.26K ﹤0.01% 2439
2025
Q3 		$3.09K Buy
+253
New +$3.5K ﹤0.01% 2502
2025
Q2 		– Sell
-279
Closed -$3.33K – 2865
2025
Q1 		$3.33K Sell
279
-27
-9% -$276 ﹤0.01% 2333
2024
Q4 		$2.57K Hold
306
– – ﹤0.01% 2462
2024
Q3 		$3.78K Buy
306
+227
+287% +$2.85K ﹤0.01% 2246
2024
Q2 		$951 Buy
+79
New +$922 ﹤0.01% 2432

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Smartleaf Asset Management's KALV Position: Q1 2026 in Review

Smartleaf Asset Management held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 575 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2300.

Smartleaf Asset Management first reported a position in KALV in Q2 2024 and has held it in 7 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Smartleaf Asset Management held 575 shares of KalVista Pharmaceuticals worth $10.6K as of Q1 2026.
  • Smartleaf Asset Management left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2300 holding.
  • Smartleaf Asset Management first reported a position in KalVista Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.